Product Slides: 3-in-1 combination inhaler

Initiated, funded and reviewed by Chiesi Limited. Date of preparation: October 2017; CHTRI20171034

This slideshow summarises key drug information for the 3-in-1 combination inhaler Trimbow® (beclometasone/formoterol/glycopyrronium), including:

  • Indications and dosage
  • Contraindications and warnings
  • Interactions
  • Use in pregnancy and lactation
  • Adverse effects
  • Mechanism of action
  • Clinical trial data

Click here to view Trimbow® (beclometasone/formoterol/glycopyrronium) and Fostair® (beclometasone/formoterol) prescribing information (PDF)

Napp
Chiesi Limited

Chiesi Limited is a privately owned UK company with a strong track record in bringing high quality, innovative medicines to UK health professionals and their patients. We believe in excellence and delivering on our promises to the NHS, patients, our business partners and each other. We strive to offer new medicines and initiatives that meet genuine needs, make a positive difference to patients’ lives and support the NHS in delivering effective, high-quality, sustainable healthcare.

This article was initiated, funded and reviewed by Chiesi Limited for MIMSconnect

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

MIMS Product Slides

Product overviews prepared by the MIMS team, in a handy slide format.

Click here

Slides are initiated, funded & reviewed by the companies specified.

MIMS app

Access the full drug database and quick-reference tables on the go

Find out more